Histone Deacetylase Inhibitors: Current Status in Treatment of Leukemia

Leukemia, one of leading cancer occurs by the acquisition of gene mutations that confer deregulated proliferation and impaired differentiation. Several histone decaetylase inhibitors (HDACi) have exhibited significant protection against the growth of tumor cells in vitro as well as in vivo. Thus it is anticipated that some HDACi could be efficient anti-leukemic drugs. Here, we summarize the current status of different types of HDACi and their clinical role in therapy of different types of leukemia.